Form 4: Chromocell Therapeutics CEO Acquires Additional Shares Through Revocable Trust

CEO Francis Knuettel II reports purchases of Chromocell Therapeutics Corp [CHRO] common stock through the Lara Knuettel Revocable Trust on September 10 and 11, 2024.

Summary

• Francis Knuettel II, CEO, President, CFO, Treasurer & Secretary of Chromocell Therapeutics Corp, reported the purchase of common stock through the Lara Knuettel Revocable Trust.
• On September 10, 2024, 6,500 shares were purchased at a weighted average price of $0.89 per share.
• On September 11, 2024, 5,500 shares were purchased at a weighted average price of $0.94 per share.
• Following these transactions, the Lara Knuettel Revocable Trust beneficially owns 542,510 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports stock purchases by an insider, which can be seen as a positive signal, but without further context, it's difficult to gauge the overall impact.

Positives

• The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider buying is often monitored by investors as an indicator of management's view of the company's valuation and prospects. However, it is only one data point and should be considered alongside other factors.

Stakeholder Impact

• Shareholders may view the CEO's stock purchase as a positive signal.

Key Dates

Keywords

Chromocell Therapeutics, Francis Knuettel II, insider trading, Form 4, stock purchase, Lara Knuettel Revocable Trust, CHRO